U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Showing 1 - 10 of 59 results

Status:
US Approved Rx (2013)
First approved in 2013

Class (Stereo):
CHEMICAL (ACHIRAL)



Bazedoxifene acetate (WAY-140424; TSE-424) is an oral, nonsteroidal, indole-based selective estrogen-receptor modulator developed by Ligand Pharmaceuticals in collaboration with Wyeth Pharmaceuticals (NJ, USA) (now Pfizer) . It was developed using ra...
Status:
US Approved Rx (2014)
First approved in 2003

Class (Stereo):
CHEMICAL (ACHIRAL)



Ibandronic acid (INN) or ibandronate sodium (USAN) is a potent bisphosphonate drug developed by Hoffman La Roche and used in the prevention and treatment of osteoporosis and metastasis-associated skeletal fractures in people with cancer. Ibandronate ...
Status:
US Approved Rx (2002)
First approved in 2001

Class (Stereo):
CHEMICAL (ACHIRAL)



Zoledronic acid (Reclast, Aclasta, Zometa) is an intravenous, highly potent amino-bisphosphonate approved worldwide, including in the USA, EU and Japan for use in patients with primary or secondary osteoporosis or low bone mass (approved indications ...
Status:
US Approved Rx (2007)
First approved in 1998

Class (Stereo):
CHEMICAL (ACHIRAL)



Risedronic acid is a pyridinyl bisphosphonate that inhibits osteoclast-mediated bone resorption and modulates bone metabolism. The action of risedronate on bone tissue is based partly on its affinity for hydroxyapatite, which is part of the mineral m...
Status:
US Approved Rx (2021)
First approved in 1940

Class (Stereo):
CHEMICAL (ABSOLUTE)



Estradiol benzoate is the synthetic benzoate ester of estradiol, a steroid sex hormone vital to the maintenance of fertility and secondary sexual characteristics in females. As the primary, most potent estrogen hormone produced by the ovaries, estrad...
Status:
Investigational

Class (Stereo):
CHEMICAL (RACEMIC)



SB-203580 was originally prepared as inflammatory cytokine synthesis inhibitor that subsequently was found to be selective inhibitor of p38 MAP kinase. SB-203580 is a p38 MAPK inhibitor with IC50 of 0.3-0.5 uM in THP-1 cells, 10-fold less sensitive t...
Status:
Investigational

Class (Stereo):
CHEMICAL (ABSOLUTE)

Targets:


Odanacatib is a potent, selective, and neutral cathepsin K inhibitor, an enzyme involved in bone resorption. Merck & Co was developing odanacatib, a once-weekly, oral Odanacatib, for the treatment of postmenopausal osteoporosis and osteoporosis i...
SB-273005 is one in a series of orally active nonpeptide vitronectin αvβ3 inhibitors. SB-273005 had been in phase I clinical trials by GlaxoSmithKline for the treatment of postmenopausal osteoporosis and rheumatoid arthritis (RA). However, this resea...
Status:
US Previously Marketed
First approved in 1960

Class (Stereo):
CHEMICAL (ABSOLUTE)



Metandienone is an orally active synthetic anabolic-androgenic steroid. In 1970, the FDA accepted that Metandienone (Dianabol) was “Probably Effective” in treating post-menopausal osteoporosis and pituitary-deficient dwarfism. Methandrostenolone is s...
Status:
US Previously Marketed
First approved in 1941

Class (Stereo):
CHEMICAL (ACHIRAL)



Diethylstilbestrol is a synthetic non-steroidal estrogen. It is used in the treatment of menopausal and postmenopausal disorders, prostate cancer and in the prevention of miscarriage or premature delivery in pregnant women prone to miscarriage or pre...